MV BioTherapeutics aims at delivering
clinical proof of concept for its lead programs.

ApyraMed Programs

 Enteropathies and cancer

Inflammatory Bowel Disease (IBD) - MV-010, SNP-apyrase

Cancer Immunotherapy - MV-004, recombinant-apyrase

Dysbiosis - MV-004, recombinant-apyrase

ApyraVax Programs

Mucosal infections

Undisclosed target - MV-005